2026-08-10 · SEMAGLUTIDE · TopGLP1Providers Data Desk

Wegovy HD (7.2 mg): the new top dose, priced against everything else

Wegovy HD is semaglutide 7.2 mg — triple the previous maximum weekly dose — approved by the FDA on March 19, 2026 for adults with obesity (or overweight plus a weight-related condition) who have already tolerated 2.4 mg for at least four weeks. The headline trial result: about 20.7% average body-weight reduction at 72 weeks in STEP UP (efficacy estimand; 18.7% treatment-policy), with 31.2% of participants losing 25% or more — semaglutide results that, for the first time, sit in tirzepatide’s territory. The headline price: $399/month cash through NovoCare↗, a $50 step over the $349 standard-dose pen. Everything a cash payer needs to weigh — HD vs 2.4 mg, vs the pill, vs the new $249 twelve-month brand subscription, vs the compounded lane — is priced below with sources.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

The approval, in three verifiable facts. One: Wegovy HD cleared the FDA on March 19, 2026 under the Commissioner’s National Priority Voucher program — a 54-day review against the usual ten-to-twelve months, the first GLP-1 approved through that pathway — with US availability from April (Novo Nordisk announcement). Two: the label is an escalation label — HD is for people who tolerated 2.4 mg for ≥4 weeks and need further reduction, not a starting dose. Three: the evidence base is STEP UP (~1,400 adults, 72 weeks: 20.7% mean loss, efficacy estimand) and STEP UP T2D (~500 adults with type 2 diabetes: 14.1%), with the safety ledger showing the cost of the extra milligrams — more GI events, dose reductions in 18.5% (vs 12.4% at 2.4 mg), and a distinctive altered-skin-sensation signal (dysesthesia, ~22% vs ~6%) — though discontinuation stayed low at 5.4% (Healio). The clinical translation is a prescriber’s, not ours; the pricing translation is exactly ours.

What HD costs, against every other way to buy semaglutide. The August 2026 cash board, captured from NovoCare’s own published pricing: Wegovy HD 7.2 mg — $399/month; standard pens (0.25–2.4 mg) — $349/month with a $199 two-fill intro for new patients; the oral pill — from $149/month (1.5 and 4 mg; the $149 rate on 4 mg is a limited offer through August 31, 2026, then $199) to $299 at 9 and 25 mg. And the March 31, 2026 development most coverage missed: the first brand multi-month subscription, sold through Ro, WeightWatchers, and LifeMD↗ — pens at $329/$299/$249 on 3/6/12-month commitments. Stacked into years: an HD year runs $4,788; a standard-pen year $4,188 monthly-billed or $2,988 on the 12-month subscription; a low-dose pill year from $1,788. The compounded comparison column: verified semaglutide programs run $133–$348/month all-in in this index (broad-availability floor $146), with NexLife↗’s dose-flat $165 ($145 on its 12-month plan) as the flat-price benchmark — but note the asymmetry: no compounded program can sell a 7.2 mg-equivalent with STEP UP behind it, because the HD dose-response data belongs to the approved product alone.

What HD changes strategically. Three things. It compresses the molecule gap: semaglutide at 7.2 mg (~20%) now brackets tirzepatide’s SURMOUNT-5 average (~20% at max tolerated dose), so the “tirzepatide or bust” heuristic weakens for people already on semaglutide — the escalation path (2.4 → 7.2) may beat a molecule switch, at $399 vs Zepbound vials’ $449 with its 45-day refill condition. It reshuffles the cash ladder: $50/month buys the step from 2.4 to 7.2 — $600/year for the incremental dose-response, which is either the best value on the board or unnecessary, depending entirely on whether 2.4 mg already did the job. And it squeezes compounded semaglutide from above exactly as the pill squeezes it from below: the approved lane now runs $149–$399 across four intensity tiers, leaving the compounded case resting on price-at-the-floor, dose-flat structure, and individualized dosing — the three things this index measures. The decision sequence, in order: insurance first (the coverage playbook — HD sits on the same Wegovy label), then the brand-vs-compounded analysis, then your own horizon math. Escalating to HD itself is a clinical call with a four-week tolerance gate built into the label — which is the FDA’s way of saying what this site always says: prescriber first, price second.

HD versus tirzepatide: the head-to-head that just got interesting. Until March, the efficacy argument was simple — tirzepatide's ~20% SURMOUNT-5 average versus semaglutide 2.4 mg's ~14% — and it priced accordingly in every lane. Wegovy HD scrambles that: ~20% average loss on semaglutide's own label, at $399 cash. Against Zepbound vials at $449 maintenance (with the 45-day refill condition attached), HD is now the cheaper way to buy top-tier approved efficacy for many cash payers — and for the large population already on semaglutide, escalation avoids the titration restart, the new-molecule side-effect lottery, and the switching logistics a tirzepatide move requires. What tirzepatide keeps: the dual-agonist mechanism, the option of the compounded lane's $215 floor, and a head-to-head trial record at maximum tolerated doses that HD has not run against. The honest framing is that the molecules now bracket each other rather than rank cleanly — which moves the decision to structure and price, where the cost comparison and a prescriber's read of your history settle it.

Insurance and HD: same label, same gate, one new wrinkle. Because HD supplements the existing Wegovy label rather than launching as a separate product, it inherits Wegovy's coverage machinery: where a plan covers Wegovy for weight management, HD rides the same prior-authorization pathway, and the commercial savings-card program lists it explicitly (the published offer structure runs $199 intro fills through year-end, then $349 standard pens and $399 HD for self-pay-through-savings patients). The wrinkle is documentation: HD's label requires tolerating 2.4 mg for at least four weeks first, which means the PA trail should already exist by the time escalation is requested — a rare case where the paperwork sequence works in the patient's favor. The unchanged rule outranks all of it: any real coverage beats every cash figure on this page, so the free phone call to the number on your insurance card still comes first; the coverage playbook sequences the rest, appeals included.

The escalation math, run three ways. Way one, incremental: moving from the $349 pen to $399 HD costs $50/month — $600/year — for the step from ~15% average loss territory to ~20%; if 2.4 mg stalled short of goal, that is among the cheapest evidence-backed upgrades in medicine, and if 2.4 mg finished the job it buys side-effect risk and nothing else. Way two, committed: the new brand subscription reprices the comparison — a 12-month standard-pen commitment at $249 means a patient weighing HD monthly against committed 2.4 mg is really weighing $4,788 against $2,988, a $1,800 annual gap that the extra efficacy has to justify (HD is not yet listed in the published subscription tiers — a fact worth re-checking quarterly, since its addition would collapse this gap). Way three, downshift-later: several clinicians frame HD as a finite push — escalate to reach goal, then return to 2.4 mg or below for maintenance — which turns the $399 into a temporary line item rather than a forever price, and connects this article to its sibling on maintenance-dose strategy. All three ways end at the same desk: the label's four-week tolerance gate makes escalation a supervised decision by construction.

What to watch between now and year-end. Four dated items will move this page's numbers. The oral pill's $149 rate at 4 mg is a limited offer through August 31, 2026 (then $199) — the entry price of the whole semaglutide board shifts within weeks. The savings-offer structure as published runs through December 31, 2026, with pricing beyond it unannounced. The brand subscription roster (Ro, WeightWatchers, LifeMD at launch, with more telehealth partners announced as coming) determines how widely the $249 committed rate spreads — and whether HD joins it. And the FDA's pending 503B rule will decide how much of the compounded semaglutide lane survives to keep pressuring brand prices from below. This index re-verifies monthly and stamps every figure with its capture date precisely because a page like this one is a snapshot of a moving market: the numbers above are true as of 2026-08-09–2026-08-10, the sources are linked, and the changelog will say so the day any of them moves.

Facts above verified August 10, 2026 against NovoCare/Novo Nordisk published pricing and the March 19, 2026 approval announcements; trial figures as reported from STEP UP and STEP UP T2D. Educational, not medical advice; escalation decisions belong with a licensed clinician.